We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
76
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$14.1M 0.33%
1,305,825
+10,600
+0.8% +$114K
MGNX icon
77
MacroGenics
MGNX
$259M
$13.8M 0.32%
857,205
+215,389
+34% +$4.05M
COLL icon
78
Collegium Pharmaceutical
COLL
$882M
$13.5M 0.31%
725,000
-175,000
-19% -$3.41M
NVCR icon
79
NovoCure
NVCR
$2.02B
$13.1M 0.3%
175,000
– –
WHWK
80
Whitehawk Therapeutics
WHWK
$259M
$13M 0.3%
538,835
-225,866
-30% -$5.67M
RIGL icon
81
Rigel Pharmaceuticals
RIGL
$778M
$12.9M 0.3%
486,020
+6,680
+1% +$202K
AKRO
82
DELISTED
Akero Therapeutics
AKRO
$12.4M 0.29%
587,101
+18,400
+3% +$408K
KDNY
83
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.7M 0.27%
720,349
+32,200
+5% +$458K
FOLD
84
DELISTED
Amicus Therapeutics
FOLD
$11.7M 0.27%
1,012,506
– –
CYPH
85
Cypherpunk Technologies Inc
CYPH
$72.4M
$11.4M 0.26%
352,057
+1,230
+0.4% +$34.1K
ABOS icon
86
Acumen Pharmaceuticals
ABOS
$176M
$10.6M 0.25%
1,571,918
-7,273
-0.5% -$79.9K
AUPH icon
87
Aurinia Pharmaceuticals
AUPH
$2.06B
$10.5M 0.24%
457,173
-156,096
-25% -$3.7M
CGEM icon
88
Cullinan Oncology
CGEM
$1.18B
$9.97M 0.23%
646,078
-429,834
-40% -$8.57M
OHPAU
89
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.85M 0.23%
1,000,000
– –
OKUR
90
OnKure Therapeutics
OKUR
$164M
$9.77M 0.23%
114,319
– –
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$9.52M 0.22%
3,807,662
+213,777
+6% +$840K
OLK
92
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$9.37M 0.22%
515,000
+10,000
+2% +$247K
NRIX icon
93
Nurix Therapeutics
NRIX
$2.69B
$9.29M 0.21%
321,050
+2,600
+0.8% +$78.8K
MREO
94
Mereo BioPharma
MREO
$43.5M
$8.94M 0.21%
5,585,621
+752,643
+16% +$1.51M
BMEA icon
95
Biomea Fusion
BMEA
$92.1M
$8.68M 0.2%
1,165,582
– –
ADAP
96
DELISTED
Adaptimmune Therapeutics
ADAP
$8.31M 0.19%
2,215,588
+25,800
+1% +$117K
VINC
97
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$8.25M 0.19%
40,460
+445
+1% +$111K
FULC icon
98
Fulcrum Therapeutics
FULC
$286M
$8.08M 0.19%
456,990
+1,700
+0.4% +$33.7K
NKTX icon
99
Nkarta
NKTX
$176M
$7.79M 0.18%
507,248
+4,100
+0.8% +$70.3K
PRTK
100
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.62M 0.18%
1,697,105
+32,091
+2% +$152K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.